The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine

Basic Clin Pharmacol Toxicol. 2008 Jan;102(1):15-24. doi: 10.1111/j.1742-7843.2007.00159.x. Epub 2007 Nov 28.

Abstract

3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a known neurotoxin in animals. This review discusses the history, pattern of use, pharmacology, acute and long-term effects of MDMA. Emphasis is given to the concern that MDMA may induce long-term cognitive and psychiatric effects. MDMA is an illegal substance, and investigations of the effects of exposure in human beings have limitations and weaknesses. There are numerous studies suggesting a correlation between MDMA exposure and psychopathology, and that the psychotropic effects may be long-lasting or permanent. However, it is not possible to conclude that there is a causal relationship between exposure and the increased psychopathology observed in MDMA users. Longitudinal studies are needed to assess whether MDMA causes persistent cognitive impairment and/or psychiatric symptoms in human beings.

Publication types

  • Review

MeSH terms

  • Animals
  • Cognition Disorders / chemically induced*
  • Cognition Disorders / physiopathology
  • Dose-Response Relationship, Drug
  • Half-Life
  • Hallucinogens / adverse effects*
  • Hallucinogens / pharmacokinetics
  • Humans
  • Illicit Drugs / adverse effects*
  • Illicit Drugs / pharmacokinetics
  • Mental Disorders / chemically induced*
  • Mental Disorders / physiopathology
  • N-Methyl-3,4-methylenedioxyamphetamine / adverse effects*
  • N-Methyl-3,4-methylenedioxyamphetamine / pharmacokinetics
  • Substance-Related Disorders*
  • Time Factors

Substances

  • Hallucinogens
  • Illicit Drugs
  • N-Methyl-3,4-methylenedioxyamphetamine